tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Halozyme raises FY23 non-GAAP EPS view to $2.65-$2.75 from $2.50-$2.65

Raises FY23 revenue view to $825M-$845M from $815M-$845M. Consensus is for FY23 EPS $2.61 and for revenue $823.06M. Raises FY23 EBITDA view to $420-$440M from $415M-$440M.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on HALO:

Disclaimer & DisclosureReport an Issue

1